(UroToday.com) Immunotherapeutic approaches have gained an increasingly large role in the treatment of many cancers. In urologic oncology, there is a large role in the first-line management of patients with metastatic renal cell carcinoma, in Bacillus Calmette-Guerin (BCG)-refractory non-muscle invasive bladder cancer, and in advanced bladder cancer. In addition to monotherapy, immunotherapy is increasingly being utilized in combination with chemotherapy. In a session of the Best Poster Presentations in Health Services and Other Research at this year’s Society of Urologic Oncology (SUO) virtual annual meeting, Dr. Mary Hall presented data from a meta-analysis examining the relative toxicity associated with combined chemoimmunotherapy compared to chemotherapy alone.